Peter H Fuller

USPTO Granted Patents = 18 (Patent Applications = 11)

EPO Patents = 13 (Patent Applications = 19)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Wakefield, MA (US) (2018)
New York, NY (US) (2015 - 2019)
Boston, MA (US) (2019 - 2020)
Ashland, MA (US) (2017 - 2024)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

2 out of 832,680

Other

patents

Years Active: 2015-2025

where 'Filed Patents' based on already Granted Patents

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12319671 - 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2025-06-03),

2. 12030872 - N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2024-07-09),

3. 11174248 - Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-16),

4. 11161854 - Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof (2021-11-02),

5. 10875847 - Aminopyrazoles as selective janus kinase inhibitors (2020-12-29),

6. 10766883 - Aminopyrazoles as janus kinase inhibitors (2020-09-08),

7. 10689369 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2020-06-23),

8. 10442819 - Tricyclic compounds as inhibitors of mutant IDH enzymes (2019-10-15),

9. 10376729 - Exercise device for paddle sports (2019-08-13),

10. 10344000 - Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-07-09),

11. 10287272 - Substituted indazole compounds as RORgammaT inhibitors and uses thereof (2019-05-14),

12. 10221142 - Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof (2019-03-05),

13. 10072025 - Ethyl N-boc piperidinyl pyrazolo pyridones as Janus kinase inhibitors (2018-09-11),

14. 10059705 - Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors (2018-08-28),

15. 9957265 - N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors (2018-05-01),

Certainly! Here's the article about inventor Peter H Fuller:

Title: Inventor Spotlight: Peter H Fuller

Introduction:

Peter H Fuller, an innovator based in Ashland, MA (US), is a prolific inventor with a total of 14 patents to his name. His groundbreaking work focuses on developing compounds that serve as potent inhibitors of the LRRK2 kinase, with potential applications in treating Parkinson's Disease and other related disorders.

Latest Patents:

1. Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors: This patented invention revolves around certain reversed indazole compounds that demonstrate high efficacy in inhibiting the LRRK2 kinase. These compounds have shown promise in the treatment and prevention of diseases associated with LRRK2 kinase activity.

2. Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors: Another notable patent by Peter H Fuller, focusing on spiro[2.2]pentane-carbonitrile derivatives that exhibit strong inhibitory effects on the LRRK2 kinase. These compounds hold potential for addressing various illnesses linked to LRRK2 kinase dysregulation.

Career Highlights:

Peter H Fuller has contributed his expertise to esteemed companies such as Merck Sharp & Dohme Corporation and Intervet Inc., where he has spearheaded innovative research projects to advance the field of pharmaceuticals and drug development. His dedication to pioneering novel solutions underscores his commitment to driving progress in the healthcare industry.

Collaborations:

Throughout his career, Peter H Fuller has collaborated closely with industry peers, including notable individuals such as Mark E Scott and Blair T Lapointe. Together, they have synergized their efforts to push the boundaries of scientific discovery and bring forth impactful innovations with the potential to transform patient care.

Conclusion:

Inventor Peter H Fuller's relentless pursuit of scientific excellence and his significant contributions to the development of LRRK2 inhibitors highlight his invaluable presence in the realm of pharmaceutical research. His patents stand as a testament to his ingenuity and commitment to advancing medical science for the benefit of individuals worldwide.

I hope you find this information about inventor Peter H Fuller insightful and engaging!

This text is generated by artificial intelligence and may not be accurate.